Antihyperlipidemic compounds

PCSK9-IN-10 is a potent and orally active PCSK9 inhibitor with an IC 50 value of 6.4 µM. PCSK9-IN-10 increases the expression of LDLR protein and decreases the expression of PCSK9. PCSK9-IN-10 reduces atherosclerosis progression. PCSK9-IN-10 has the

PCSK9-IN-10 is a potent and orally active PCSK9 inhibitor with an IC 50 value of 6.4 µM. PCSK9-IN-10 increases the expression of LDLR protein and decreases the expression of PCSK9. PCSK9-IN-10 reduces atherosclerosis progression. PCSK9-IN-10 has the

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the

SB-633825 is a potent and ATP-competitive inhibitor of TIE2 , LOK (STK10) and BRK with IC 50 s of 3.5 nM, 66 nM, 150 nM, respectively. SB-633825 can inhibit cancer cell growth and angiogenesisIn VitroSB-633825 inhibits TIE2 Tyrosine-protein kinase

SB-633825 is a potent and ATP-competitive inhibitor of TIE2 , LOK (STK10) and BRK with IC 50 s of 3.5 nM, 66 nM, 150 nM, respectively. SB-633825 can inhibit cancer cell growth and angiogenesisIn VitroSB-633825 inhibits TIE2 Tyrosine-protein kinase

SB-633825 is a potent and ATP-competitive inhibitor of TIE2 , LOK (STK10) and BRK with IC 50 s of 3.5 nM, 66 nM, 150 nM, respectively. SB-633825 can inhibit cancer cell growth and angiogenesisIn VitroSB-633825 inhibits TIE2 Tyrosine-protein kinase

SB-633825 is a potent and ATP-competitive inhibitor of TIE2 , LOK (STK10) and BRK with IC 50 s of 3.5 nM, 66 nM, 150 nM, respectively. SB-633825 can inhibit cancer cell growth and angiogenesisIn VitroSB-633825 inhibits TIE2 Tyrosine-protein kinase

Silybin B (Silibinin B), a flavonolignan separated from Silybum marianum, has anti-tumor activity. Silybin B is the most potent antifibrillogenic and anti-oligomeric component of silymarin and proposes it as a promising anti Alzheimer’s disease

Silybin B (Silibinin B), a flavonolignan separated from Silybum marianum, has anti-tumor activity. Silybin B is the most potent antifibrillogenic and anti-oligomeric component of silymarin and proposes it as a promising anti Alzheimer’s disease

Silybin B (Silibinin B), a flavonolignan separated from Silybum marianum, has anti-tumor activity. Silybin B is the most potent antifibrillogenic and anti-oligomeric component of silymarin and proposes it as a promising anti Alzheimer’s disease

Silybin B (Silibinin B), a flavonolignan separated from Silybum marianum, has anti-tumor activity. Silybin B is the most potent antifibrillogenic and anti-oligomeric component of silymarin and proposes it as a promising anti Alzheimer’s disease

t-Boc-N-Amido-PEG2-Ms is a PEG derivative that contains a Boc protecting group and a mesyl group. The t-Boc group can be removed under acidic conditions. The mesyl group is a good leaving group for nucleophilic substitution reactions. The